Abstract: A process for preparing a crystalline form of candesartan cilexetil referred to as Form I, which has a content of Form II lower than 1% (w/w), is described. The process includes a seeding stage with a crystalline product, which mainly includes Form I, and a digestion stage. The invention also relates to the crystalline form, the pharmaceutical compositions containing it and its use for the preparation of a medicament for the treatment of hypertension. Candesartan cilexetil Form I has shown good stability under accelerated stability conditions, when the content of Form II is lower than 1% w/w.

Abstract: This invention relates to a process for obtaining levofloxacin free from salts. In this process the starting product used is the compound (V), alkaline hydrolysis of which within a water-(C1-C4)alcohol mixture, and subsequent neutralisation and separation of the salts, leads to levofloxacin free from salts, without need to carry out any final step of extraction and without using halogenated solvents. One characteristic of the process described is that no extractions are necessary in the final step of the process.

Abstract: Said addition salts have a molar ratio between azithromycin and citric acid such as to provide a pH comprised between 4.0 and 8.0 in a 10% aqueous solution. The process for preparing said salts comprises: a) dissolving azithromycin in a solvent or mixture of solvents; b) adding citric acid; and c) isolating the product obtained by crystallisation. The addition salts of azithromycin and citric acid are stable and soluble in aqueous medium, being useful antibacterial and antiprotozoan agents.